Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Other Non-Current Liabilities (2016 - 2026)

Mimedx's Other Non-Current Liabilities history spans 16 years, with the latest figure at $5.1 million for Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities fell 31.98% to $5.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.1 million, a 31.98% decrease, with the full-year FY2025 number at $5.4 million, down 27.24% from a year prior.
  • Other Non-Current Liabilities hit $5.1 million in Q1 2026 for Mimedx, down from $5.4 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for MDXG hit a ceiling of $7.5 million in Q1 2025 and a floor of $2.2 million in Q4 2023.
  • Historically, Other Non-Current Liabilities has averaged $4.8 million across 5 years, with a median of $4.8 million in 2022.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 53.43% in 2023 and later skyrocketed 232.12% in 2024.
  • Tracing MDXG's Other Non-Current Liabilities over 5 years: stood at $4.8 million in 2022, then plummeted by 53.43% to $2.2 million in 2023, then skyrocketed by 232.12% to $7.4 million in 2024, then dropped by 27.24% to $5.4 million in 2025, then decreased by 5.14% to $5.1 million in 2026.
  • Business Quant data shows Other Non-Current Liabilities for MDXG at $5.1 million in Q1 2026, $5.4 million in Q4 2025, and $5.5 million in Q3 2025.